Comparing the effect of liquid phase concentrated growth factors with 2% lidocaine in the management of patients with myofascial pain syndrome
- Conditions
- patients with myofascial pain syndrome.
- Registration Number
- IRCT20220610055126N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 16
Age between 15 and 80 years [=15 and =80]
Presence of at least one trigger point in the masseter or temporalis muscle, previously detected
Patient’s agreement for participation in this study.
Presence of myofascial pain within masseter muscles according to the RDC/TMD (Ia and Ib)
Patients being treated or addicted to painkillers and / or drugs that affect muscle function. Such as: muscle relaxants, anti-inflammatory, benzodiazepines
Patients with mental disorders
Patients with neuropathic pain and neurological disorders (trigeminal neuralgia)
Patients with headache
Edentulous patients
Patients after radiotherapy
Pregnancy or lactation
Pain of dental origin
Drug and/or alcohol addiction
Patients with needle phobia
Patients with bleeding disorders
Metabolic (diabetes) and vascular diseases
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pain intensity of masseter muscle trigger points, pain intensity of temporalis muscle trigger points, general pain intensity, painless opening of mouth. Timepoint: At the beginning of the study (before the start of the intervention) and 7, 14 and 28 days. Method of measurement: Visual Analogue Scale for pain intensity and measurement with a graduated millimeter with an accuracy of one millimeter for maximum mouth opening.
- Secondary Outcome Measures
Name Time Method